Overview

Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control

Status:
Terminated
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the change in hemoglobin A1c (HbA1c) from baseline to Week 12 between the 3 treatment arms.
Phase:
Phase 4
Details
Lead Sponsor:
Sanofi
Treatments:
2,4-thiazolidinedione
Insulin
Insulin Glargine
Insulin glulisine
Insulin, Globin Zinc
Metformin